Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 23, Number 11—November 2017
Research Letter

Mycobacterium shimoidei, a Rare Pulmonary Pathogen, Queensland, Australia

Timothy M. BairdComments to Author , Robyn Carter, Geoffrey Eather, and Rachel Thomson
Author affiliations: Princess Alexandra Hospital, Brisbane, Queensland, Australia (T.M. Baird, G. Eather); Metro South Clinical Tuberculosis Service, Brisbane (T.M. Baird, G. Eather, R. Thomson); Greenslopes Private Hospital, Brisbane (R. Thomson); University of Queensland, Brisbane (R. Thomson); Royal Brisbane and Womens Hospital, Brisbane (R. Carter)

Cite This Article

Abstract

Nontuberculous mycobacteria are human pathogens with increasing incidence and prevalence worldwide. Mycobacterium shimoidei is a rare cause of pulmonary disease, with only 15 cases previously reported. This series documents an additional 23 cases of M. shimoidei from Queensland, Australia, and highlights the pathogenicity and clinical role of this species.

Nontuberculous mycobacteria (NTM) are prominent human pathogens, with >150 species reported worldwide (1). Mycobacterium shimoidei is a slow-growing NTM that was first isolated in Japan in 1968, successfully gaining species status in 1975 (2). Since then, only 15 cases have been reported worldwide (310).

In Queensland, Australia, NTM is a reportable condition, requiring all isolates to be reported to the Queensland Mycobacterium Reference Laboratory. This series examines all M. shimoidei cases in Queensland during January 1, 2000– December 31, 2014.

We extracted data from the Queensland Notifiable Condition System with ethics approval obtained from the Metro North Human Research Ethics Committee (HREC/15/QPCH/65). Confirmatory testing was conducted at the Queensland Mycobacterium Reference Laboratory using 2 methods: the Hain Genotype CM/AS Line Probe Assays (Hain Lifescience, Nehren, Germany) and 16S rRNA sequencing.

We obtained clinical information from treating physicians and patient medical records. We recorded each isolate as being likely clinically significant, possibly significant, or unlikely significant, and as being consistent or not with NTM lung disease according to the 2007 American Thoracic Society and Infectious Disease Society of America criteria.

Specimens from 23 patients (35 total isolates) cultured M. shimoidei in Queensland during the study period. Individual clinical characteristics, treatment, and outcomes can be seen in the Table. Previously reported cases are summarized in the Technical Appendix.

Sixteen (69.6%) patients were male (mean ± SD age 66.2 ± 12.6 years), consistent with previous case reports (310). Nine (39.1%) were classified as being likely clinically significant and 7 (30.4%) possibly significant. Ten patients (43.5%) met the 2007 American Thoracic Society and Infectious Disease Society of America criteria for having NTM lung disease. All isolates were cultured from respiratory specimens, with 15 (65.2%) isolated from sputum; 2 (8.7%) from bronchial washings; 2 (8.7%) from both bronchial washings and sputum; and 2 (17.4%) from lung tissue either with computed tomography–guided biopsy or at autopsy. Only 4 (17.4%) specimens were smear-positive by microscopy.

The most common symptoms were cough or sputum (16; 69.6%); weight loss (9; 39.1%); dyspnea (5; 21.7%); fevers or sweats (4; 17.4%); and fatigue (2; 8.7%). Cough and sputum predominated in previous cases, but not weight loss (310). Radiology demonstrated cavitary disease in 9 patients (39.1%). Similar to our cohort, 9 of the 15 previously reported cases had cavities, highlighting a potentially distinguishing feature of M. shimoidei lung disease (37).

The most common associated concurrent conditions were obstructive airway disease (10; 43.5%), bronchiectasis (6; 26.1%), gastroesophageal reflux disease (4; 17.4%), and malnutrition (3; 13.0%). Underlying chronic lung disease was also present in previously reported cases and included chronic obstructive pulmonary disease, past tuberculosis, pneumoconiosis, and bronchiectasis (310).

Although 16 patients (69.5%) were deemed to have either likely or possibly clinically significant disease, only 6 (26.0%) underwent medical treatment, with 7 (30.4%) being actively observed. These low treatment numbers may reflect a lack of knowledge in relation to M. shimoidei; however, they may also be an indirect result of the underlying comorbidities and poor functional status of infected patients.

When medical treatment was offered, however, 5 of the 6 patients improved or had stable disease, with the sixth patient dying of lung cancer while undergoing antimicrobial therapy. Of the 7 patients who were observed, 3 remained stable, 2 improved, and 2 died of either chronic lung disease or progression of their M. shimoidei infection. In comparison, 6 of the 15 previous cases in the literature improved with medical treatment, with 4 dying during treatment and 1 remaining stable with observation alone (310). Although this relatively high death rate may reflect the nature of the patients’ comorbidities, it still highlights the clinical significance of M. shimoidei if isolated.

Although none of the Queensland cohort underwent drug susceptibility testing, review of previous cases suggests that a combination of rifabutin, ethambutol, and clarithromycin may be an effective drug regimen, with moxifloxacin/levofloxacin, sulfamethoxazole, pyrazinamide, and linezolid as other potential agents (37).

Our study has several limitations. First, it is a retrospective case series with data extracted from a passive surveillance system. Even though all laboratory-confirmed cases were captured, it is possible that not all patients with M. shimoidei infection received this diagnosis or were able to provide an appropriate specimen for identification. Futhermore, due to both the clinical characteristics being reported by various treating physicians and a large proportion not having complete clinical or follow-up data available, we may have captured inaccurate or inconsistent data.

This case series highlights the clinical significance and pathogenicity of M. shimoidei. Cases have been isolated only from respiratory specimens, occur predominantly in male patients with underlying chronic lung disease, and commonly present with cavitary disease. Although illness and death are associated with M. shimoidei infection, a reasonable outcome can be achieved with treatment. Possible drug regimens involve a combination of rifabutin, ethambutol, and clarithromycin, with moxifloxacin/levofloxacin, sulfamethoxazole, pyrazinamide, and clofazimine also potentially being useful. Increased recognition and understanding of this pathogenic organism are necessary to improve patient outcomes.

Dr. Baird is a fellow in respiratory and sleep medicine at the Princess Alexandra Hospital and the Metro South Clinical Tuberculosis Service in Brisbane, Australia. His clinical and research interests are in pulmonary infections, particularly tuberculosis and nontuberculous mycobacterial disease.

Top

Acknowledgment

We acknowledge all the clinicians and administration staff involved in the gathering and provision of relevant clinical information, alongside Chris Coulter, Sushil Pandey, and the Queensland Mycobacterium Reference Laboratory for the ongoing provision of TB and NTM pathology services in Queensland.

Top

References

  1. Thomson  RM; NTM working group at Queensland TB Control Centre and Queensland Mycobacterial Reference Laboratory. Changing epidemiology of pulmonary nontuberculous mycobacteria infections. Emerg Infect Dis. 2010;16:157683. DOIPubMed
  2. Tsukamura  M, Shimoide  H, Shaefer  WB. A possible new pathogen of group iii Mycobacteria. J Gen Microbiol. 1975;88:37780. DOIPubMed
  3. Takayama  S, Tominaga  S, Tsukada  Y, Ohkochi  M, Inase  N. [A case of pulmonary Mycobacterium shimoidei infection]. Kekkaku. 2006;81:53741.PubMed
  4. Kanaji  N, Kushida  Y, Bandoh  S, Ishii  T, Haba  R, Tadokoro  A, et al. Membranous glomerulonephritis associated with Mycobacterium shimoidei pulmonary infection. Am J Case Rep. 2013;14:5437. DOIPubMed
  5. Galizzi  N, Tortoli  E, Gori  A, Morini  F, Lapadula  G. A case of mild pulmonary disease due to Mycobacterium shimoidei with a favorable outcome. J Clin Microbiol. 2013;51:34678. DOIPubMed
  6. Tortoli  E, Simonetti  MT. Isolation of Mycobacterium shimoidei from a patient with cavitary pulmonary disease. J Clin Microbiol. 1991;29:17546.PubMed
  7. Mayall  B, Gurtler  V, Irving  L, Marzec  A, Leslie  D. Identification of Mycobacterium shimoidei by molecular techniques: case report and summary of the literature. Int J Tuberc Lung Dis. 1999;3:16973 http://www.ncbi.nlm.nih.gov/pubmed/10091886.PubMed
  8. Heller  R, Jaulhac  B, Charles  P, De Briel  D, Vincent  V, Bohner  C, et al. Identification of Mycobacterium shimoidei in a tuberculosis-like cavity by 16S ribosomal DNA direct sequencing. Eur J Clin Microbiol Infect Dis. 1996;15:1725. DOIPubMed
  9. Sundman  K, Chryssanthou  E, Petrini  B. Mycobacterium shimoidei, an easily misdiagnosed non-tuberculous pulmonary mycobacterium. Scand J Infect Dis. 2000;32:4501.PubMed
  10. Koukila-Kähkölä  P, Paulin  L, Brander  E, Jantzen  E, Eho-Remes  M, Katila  ML. Characterisation of a new isolate of Mycobacterium shimoidei from Finland. J Med Microbiol. 2000;49:93740. DOIPubMed

Top

Table

Top

Cite This Article

DOI: 10.3201/eid2311.170999

Table of Contents – Volume 23, Number 11—November 2017

Comments

Please use the form below to submit correspondence to the authors or contact them at the following address:

Timothy M. Baird, Metro South Clinical Tuberculosis Service and Respiratory and Sleep Medicine Department, Princess Alexandra Hospital, Queensland Health, 199 Ipswich Rd, Wooloongabba, Queensland, 4102, Australia

Send To

character(s) remaining.

Comment submitted successfully, thank you for your feedback.

Top

Page created: October 17, 2017
Page updated: October 17, 2017
Page reviewed: October 17, 2017
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external